We’re delighted to announce the launch of the Flowflex™ SARS-COV-2 Antigen Rapid Test, a lateral flow chromatographic immunoassay for the qualitative detection the nucleocapsid protein antigen from SARS-CoV-2 in nasal swab specimens.
The test is intended to help in the diagnosis of individuals who are suspected of active COVID-19 disease by their healthcare provider within the first 7 days of the onset of symptoms.
Flowflex™ is CE marked and is commercialised for sales in the United Kingdom, European Union and the Latin American Markets.
The lateral flow chromatographic immunoassay has a high relative sensitivity (97.1%), and specificity (99.6%) and is therefore highly accurate (99.3%). The Rapid Test is performed using nasal specimens, and results are available after 15 minutes.
The manufacturer is ramping up its capabilities to meet the increasing worldwide market demand for reliable testing.
Test kits are for professional use only.
To find out more visit the product page HERE, or for enquiries and orders please submit the contact form below.